Businessweek

Oenon Holdings, Inc. engages in alcoholic beverages, food products, enzymes and pharmaceuticals, real estate, and bioethanol businesses. It provides alcoholic beverages, including sake compounds, plum wine, processed liquors, wines, brewing and industrial alcohol, seasonings, and cocktails. The company also offers enzymes for food and industrial use comprising lactase, a lactose hydrolytic enzyme; cellulase, a paper and pulp processing enzyme; glucose isomelase, a high fructose syrup manufacturing enzyme; and Dispase, a cell dispersion enzyme. In addition, it provides drug substances, such as pravastatin, a hyperlipidemia agent; serrapeptase, an anti-inflammatoric enzyme; and voglibose, a diabetes agent, as well as produces and distributes starch for food processing. Further, the company offers diagnostic products consisting of fecal occult blood test reagents for screening colon cancer, salivary occult blood test reagents for screening periodontal disease, and urological test reagents; and health food ingredients, which include Agaricus blazei and L-arabinose. Additionally, it is involved in the purchase and sale, renting, and maintenance of real estate properties; operation of restaurants; and the provision of bioethanol and distiller's dried grains with solubles, as well as warehousing and logistics services. Oenon Holdings, Inc. was founded in 1924 and is headquartered in Tokyo, Japan.